Cadila Healthcare completes USFDA inspection of API plant
Pharma major Cadila Healthcare announced that the USFDA has successfully completed the inspection of its API manufacturing facility at Dabhasa. Following the development, the stock of the company surged by over 3 per cent on the bourses.
The company also secured the final nod from the USFDA for Valacyclovir tablets, Clomipramine Hydrochloride Capsules, Nifedipine Extended-Release Tablets and Clozapine Tablets USP among others in the month of December in 2017. The group has secured over 180 approvals and has filed over 310 ANDAs since the commencement of the filing process in the fiscal year 2003-04.
The stock hit an intraday high of Rs. 450.55 per share and an intraday low of Rs. 433.40 per share on BSE on Friday. The stock had hit its 52-week high of Rs. 558 per share on June 12, 2017 and its 52-week low of Rs. 334.35 per share on January 31, 2017 on BSE, respectively.
On Friday, the stock recorded a spurt in volume of more than 1.13 times against its average volume on BSE. At 1515 hours IST, the stock was trading at Rs. 441.90 per share, higher by 1.33 per cent, respectively.
Zydus Cadila is aspiring to become a research-based pharmaceutical company by 2020.